NCT02662569
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
See it on ClinicalTrials.gov ↗986 people
57.2%
42.8%
564 womenmiddle line = equal numbers422 men
- Phase
- PHASE3
- Paid for by
- Amgen
- Finished
- 2017-12-06
- Health conditions
- Diabetes, Hyperlipidemia, Mixed Dyslipidemia
- Who could join
- Anyone
- Ages
- 18 Years – 80 Years
- Average age
- mean 61.3 years
- Age 65+
- 37.1%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Asian 49.9% · White 42.6% · Black / African American 4.3% · More than one race 3% · American Indian / Alaska Native 0.2% · Native Hawaiian / Pacific Islander 0%
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“New York Heart Association (NYHA) class III or IV heart failure”
- No diabetes
Women with diabetes were turned away.
“Type 1 diabetes or poorly controlled type 2 diabetes”
Study titles and rules are shown in their original English.